Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized open-label comparison of BIAsp 30 + sitagliptin + metformin regimens in type 2 diabetes
2011-004930-33Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Feb 2012; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-004930-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004930-33.